Patients with non-invasive, small adenomas who exhibit normal serum prolactin levels and significant tumor shrinkage after at least two years of low-dose cabergoline treatment (0.25–0.50 mg per week) have the highest likelihood of maintaining remission following withdrawal (7–9). The gene discussed is PRL; the disease is adenoma.